Bluebird Bio Inc.

08/17/2022 | Press release | Distributed by Public on 08/17/2022 12:40

bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who[...]